

Richard K Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/475926/publications.pdf>

Version: 2024-02-01

79
papers

1,313
citations

430442

18
h-index

414034

32
g-index

79
all docs

79
docs citations

79
times ranked

2092
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronary revascularisation outcomes in patients with cancer. <i>Heart</i> , 2022, 108, 507-516.	1.2	4
2	Implications of cancer prior to and after heart transplantation. <i>Heart</i> , 2022, 108, 414-421.	1.2	5
3	Implications of screening for coexisting transthyretin amyloidosis and aortic stenosis. <i>Heart</i> , 2022, 108, heartjnl-2021-320229.	1.2	2
4	Association of soluble Flt-1 with heart failure and cardiac morphology: The MESA angiogenesis study. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 619-625.	0.3	4
5	Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1635-1646.	0.8	27
6	Bridging the gap to advance the care of individuals with cancer: collaboration and partnership in the Cardiology Oncology Innovation Network (COIN). <i>Cardio-Oncology</i> , 2022, 8, 2.	0.8	6
7	In-Hospital Characteristics and 30-Day Readmissions for Acute Myocardial Infarction and Major Bleeding in Patients With Active Cancer. <i>American Journal of Cardiology</i> , 2022, 166, 25-37.	0.7	2
8	Abstract PD5-03: Development of cardiometabolic risk factors following endocrine therapy: The pathways heart study. <i>Cancer Research</i> , 2022, 82, PD5-03-PD5-03.	0.4	0
9	Abstract PD5-01: Cardiovascular disease risk of breast cancer therapies: The pathways heart study. <i>Cancer Research</i> , 2022, 82, PD5-01-PD5-01.	0.4	0
10	Histamine H ₂ Receptor Antagonists and Heart Failure Risk in Postmenopausal Women: The Women's Health Initiative. <i>Journal of the American Heart Association</i> , 2022, 11, e024270.	1.6	3
11	Toward a More Precise Understanding of Obesity and Cancer and Cardiovascular Disease Risk. <i>JACC: CardioOncology</i> , 2022, 4, 82-84.	1.7	0
12	Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors. <i>JACC: CardioOncology</i> , 2022, 4, 53-65.	1.7	16
13	Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1647-1658.	0.8	46
14	Long-Term Outcomes and Risk Stratification of Patients With Heart Failure With Recovered Ejection Fraction. <i>American Journal of Cardiology</i> , 2022, 173, 80-87.	0.7	5
15	Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials. <i>Hematological Oncology</i> , 2022, 40, 233-242.	0.8	22
16	Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 669-675.	1.1	4
17	Novel Therapeutics for Anthracycline Induced Cardiotoxicity. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 863314.	1.1	15
18	Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3688-3691.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , 2021, 113, 513-522.	3.0	13
20	When cardiomyopathy, cancer, and COVID-19 collide: A case report. <i>Breast Journal</i> , 2021, 27, 384-386.	0.4	0
21	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009203.	2.1	14
22	SGLT2 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1375-1377.	1.2	2
23	Patient factors and outcomes associated with discordance between quantitative and qualitative cardiac PET ischemia information. <i>PLoS ONE</i> , 2021, 16, e0246149.	1.1	1
24	The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative. <i>European Journal of Heart Failure</i> , 2021, 23, 1712-1721.	2.9	19
25	Cost-effectiveness of left ventricular assist devices as destination therapy in the United Kingdom. <i>ESC Heart Failure</i> , 2021, 8, 3049-3057.	1.4	6
26	Admission respiratory status predicts mortality in COVID-19. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 569-572.	1.5	42
27	A new classification of cardio-oncology syndromes. <i>Cardio-Oncology</i> , 2021, 7, 24.	0.8	27
28	Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure. <i>Heart</i> , 2021, 107, 1364-1366.	1.2	2
29	Left Ventricular Assist Devices in Patients With Active Malignancies. <i>JACC: CardioOncology</i> , 2021, 3, 305-315.	1.7	5
30	The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic. <i>Current Oncology Reports</i> , 2021, 23, 99.	1.8	8
31	Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials. <i>JACC: Heart Failure</i> , 2021, 9, 803-806.	1.9	3
32	Trends in cardiovascular mortality of cancer patients in the US over two decades 1999-2019. <i>International Journal of Clinical Practice</i> , 2021, 75, e14841.	0.8	5
33	Combat Doxorubicin Cardiotoxicity With the Power of Mitochondria Transfer. <i>JACC: CardioOncology</i> , 2021, 3, 441-443.	1.7	5
34	Impact of malignancy on in-hospital mortality, stratified by the cause of admission: An analysis of 67 million patients from the National Inpatient Sample. <i>International Journal of Clinical Practice</i> , 2021, 75, e14758.	0.8	2
35	ATTR Amyloidosis: Current and Emerging Management Strategies. <i>JACC: CardioOncology</i> , 2021, 3, 488-505.	1.7	56
36	Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. <i>Journal of the American Heart Association</i> , 2021, 10, e022859.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Editorial commentary: Searching for the sweet spot of cardioprotection in cancer treatment related cardiotoxicity: Who will benefit?. Trends in Cardiovascular Medicine, 2020, 30, 29-31.	2.3	0
38	Left Ventricular Assist Device Inflow Cannula Insertion Depth Influences Thrombosis Risk. ASAIO Journal, 2020, 66, 766-773.	0.9	26
39	Comparison of Neurologic Event Rates Among HeartMate II, HeartMate 3, and HVAD. ASAIO Journal, 2020, 66, 620-624.	0.9	20
40	Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 414-424.	1.7	37
41	Accuracy of Doppler blood pressure measurement in HeartMate 3 ventricular assist device patients. ESC Heart Failure, 2020, 7, 4241-4246.	1.4	7
42	Constrictive Pericarditis After Lung Transplantation. JACC: Case Reports, 2020, 2, 938-942.	0.3	0
43	Intraventricular Free-Floating Thrombus in an Impella-Supported Patient. JACC: Case Reports, 2020, 2, 886-888.	0.3	4
44	Cardio-Oncology Education and Training. Journal of the American College of Cardiology, 2020, 76, 2267-2281.	1.2	41
45	Cost-Effectiveness of a Small Intrapericardial Centrifugal Left Ventricular Assist Device. ASAIO Journal, 2020, 66, 862-870.	0.9	15
46	Cost-Effectiveness of Thoracotomy Approach for the Implantation of a Centrifugal Left Ventricular Assist Device. ASAIO Journal, 2020, 66, 855-861.	0.9	18
47	Assessment of Left Ventricular, Right Ventricular, and Left Atrial Strain in Light-Chain Amyloidosis. JACC: CardioOncology, 2020, 2, 647-649.	1.7	2
48	Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative. Oncologist, 2020, 25, 712-721.	1.9	2
49	Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. ESC Heart Failure, 2020, 7, 1664-1675.	1.4	19
50	Risk of Adverse Cardiovascular Events in Cardiac Sarcoidosis Independent of Left Ventricular Function. American Journal of Cardiology, 2020, 127, 142-148.	0.7	9
51	Cardiovascular disease and COVID-19: implications for prevention, surveillance and treatment. Heart, 2020, 106, 1119-1121.	1.2	8
52	Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative. Journal of Heart and Lung Transplantation, 2020, 39, 604-606.	0.3	15
53	Comparison of 30-Day Unplanned Readmissions to the Index Versus Nonindex Hospital After Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 125, 1287-1294.	0.7	6
54	COVID-19 and acute myocardial injury: the heart of the matter or an innocent bystander?. Heart, 2020, 106, 1122-1124.	1.2	40

#	ARTICLE	IF	CITATIONS
55	Risk of cardiovascular disease in women with and without a history of breast cancer: The Pathways Heart Study.. Journal of Clinical Oncology, 2020, 38, 12016-12016.	0.8	3
56	Onset of cardiovascular disease risk factors in women with and without a history of breast cancer: The Pathways Heart Study.. Journal of Clinical Oncology, 2020, 38, 12017-12017.	0.8	0
57	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation, 2019, 140, 529-537.	1.6	81
58	Moderate or severe valvular heart disease and outcomes in allogeneic stem cell transplantation. International Journal of Cardiology, 2019, 292, 166-170.	0.8	3
59	Accuracy of Doppler blood pressure measurement in continuous-flow left ventricular assist device patients. ESC Heart Failure, 2019, 6, 793-798.	1.4	17
60	Cardiovascular Disease and Cancer: Is There Increasing Overlap?. Current Oncology Reports, 2019, 21, 47.	1.8	43
61	Cardio-Oncology and the Intersection of Cancer and Cardiotoxicity. JACC: CardioOncology, 2019, 1, 314-317.	1.7	3
62	Extracellular Volume as an Imaging Biomarker for Incident Heart Failure. Circulation: Cardiovascular Imaging, 2019, 12, e010152.	1.3	3
63	Developing and implementing a heart failure data mart for research and quality improvement. Informatics for Health and Social Care, 2019, 44, 164-175.	1.4	1
64	Small Left Ventricular Size Is an Independent Risk Factor for Ventricular Assist Device Thrombosis. ASAIO Journal, 2019, 65, 152-159.	0.9	32
65	Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation. Canadian Journal of Cardiology, 2018, 34, 978-982.	0.8	20
66	Echocardiographic Insights into the Hemodynamics of Systolic Heart Failure: Can This Guide Titration of Medical Therapy?. Journal of the American Society of Echocardiography, 2018, 31, 660-663.	1.2	1
67	Adverse Effects of Delayed Transplant Listing Among Patients With Implantable Left Ventricular Assist Devices. Journal of Cardiac Failure, 2018, 24, 243-248.	0.7	2
68	Cardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsy. Respiratory Medicine, 2018, 144, S13-S19.	1.3	20
69	Agreement between risk and priority for heart transplant: Effects of the geographic allocation rule and status assignment. Journal of Heart and Lung Transplantation, 2017, 36, 666-672.	0.3	7
70	Pulmonary function tests do not predict mortality in patients undergoing continuous-flow left ventricular assist device implantation. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1959-1970.e1.	0.4	8
71	Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	41
72	Association between preoperative peripheral blood mononuclear cell gene expression profiles, early postoperative organ function recovery potential and long-term survival in advanced heart failure patients undergoing mechanical circulatory support. PLoS ONE, 2017, 12, e0189420.	1.1	13

#	ARTICLE	IF	CITATIONS
73	Periportal fibrosis without cirrhosis does not affect outcomes after continuous flow ventricular assist device implantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 230-235.	0.4	5
74	Effect of regional competition on heart transplant waiting list outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 986-994.	0.3	9
75	Systematic donor selection review process improves cardiac transplant volumes and outcomes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 238-243.	0.4	32
76	Late Surgical Bleeding Following Total Artificial Heart Implantation. <i>Journal of Cardiac Surgery</i> , 2015, 30, 771-774.	0.3	5
77	Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. <i>American Heart Journal</i> , 2014, 168, 721-730.e3.	1.2	289
78	Percutaneous Angioplasty of Stenotic Outflow Graft Anastomosis of HeartMate II. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 700-703.	1.1	10
79	Obesity in heart failure: impact on survival and treatment modalities. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1141-1153.	0.6	2